By Abdul Menum Ali

FarmaKology Newsletter - Issue #68







March 2 · Issue #68 · View online

FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "".

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to, and happy to have you featured on our newsletter (+10K Subscribers )!

Today's Startup
Longevity Biotech
Longevity Biotech
Longevity Biotech
Longevity Biotech is developing new therapeutic drug candidates, which may have direct clinical impacts on patients lives. All of our programs are based on our Hybridtide peptide scaffold technology. Hybridtides are designed for long-acting oral administration.
Evotec SE and Chinook Therapeutics, Inc. today announced a strategic collaboration focused on the discovery and development of novel precision medicine therapies for patients with chronic kidney diseases (“CKD”). Based on Evotec’s proprietary comprehensive molecular datasets from thousands of patients across chronic kidney diseases of multiple underlying etiologies, Chinook and Evotec will jointly identify, characterise and validate novel mechanisms and discover and develop precision medicines. 
An adenovirus vector vaccine against COVID-19 by CanSino Biologics is projected to provide protection for two years if a booster shot is administered, said a scientist who played a key role in the vaccine’s development. The Chinese National Medical Products Administration granted conditional market approval to the vaccine on Thursday. The vaccine, called Ad5-nCoV, has an efficacy rate of 65.7 per cent at preventing symptomatic cases and is 90.9 per cent effective in preventing severe disease with a single injection, according to an interim analysis of late-stage human trials released in February.
Eurofins’s Clinical Enterprise, Inc. announces that it has received US Food and Drug Administration Emergency Use Authorization (EUA) for a direct-to-consumer version of its EmpowerDX COVID-19 Home Collection Kit. The Eurofins at-home COVID-19 nasal PCR kit is among the first over-the-counter at-home test kits for SARS-CoV-2 to receive EUA. With this authorization, Eurofins is able to sell the test kit directly to consumers without a prescription.
Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older.
Research & Study
Cowen Insights | RESET-ing The Treatment Paradigm For Mental Health With Pear Therapeutics by Cowen | Free Listening on SoundCloud
Job Opportunities
Upcoming Webinar
Colchicine: Evidence-Based Health Information Related to COVID-19
Did you enjoy this issue?
In order to unsubscribe, click here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue